Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: August 24, 2026
Subject: Update on Share Repurchase Programme
Novo Nordisk A/S, a leading global healthcare company headquartered in Denmark, reported on its ongoing share repurchase activities. The company employs approximately 68,800 people across 80 countries and markets products in around 170 countries.
Key Financial Metrics and Capital Allocation
This filing focuses on capital allocation via share buybacks rather than operational financial performance (revenue, profit, or cash flow). Key metrics include:
- Total Repurchase Programme Cap: Up to DKK 15 billion for a 12-month period beginning February 4, 2026.
- Specific Programme (May 6, 2026): Up to DKK 11,200,000,010.45 for B shares.
- Accumulated Repurchases (Since Feb 4, 2026): 29,929,179 B shares.
- Average Purchase Price (Since Feb 4, 2026): DKK 280.34 per B share.
- Total Transaction Value (Since Feb 4, 2026): DKK 8,390,476,831.
- Treasury Shares Held: 43,969,876 B shares (1.0% of share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Material Changes and Recent Activity
Since the last announcement on August 17, 2026, the company executed the following transactions:
| Date | Number of B Shares | Avg. Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| August 17, 2026 | 205,000 | 292.63 | 59,989,440 |
| August 18, 2026 | 210,000 | 292.60 | 61,446,140 |
| August 19, 2026 | 210,000 | 296.16 | 62,193,344 |
| August 20, 2026 | 210,000 | 299.08 | 62,807,428 |
| August 21, 2026 | 210,000 | 297.05 | 62,379,660 |
Accumulated under the May 6 programme: 15,170,000 shares for DKK 4,590,476,842.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total programme limit of DKK 15 billion during the 12-month period starting February 4, 2026. As of August 21, 2026, approximately DKK 6.6 billion remains available under the total programme cap.
Risks and Contingencies: The filing does not disclose new operational risks or contingencies. The repurchase programme is conducted in accordance with Article 5 of Regulation No 596/2014 (MAR) and the Safe Harbour Rules.
Financial Performance: The filing text does not provide a clear value for revenue, profit, cash flow, margins, or debt levels for the reporting period.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 15 billion total repurchase programme (approx. DKK 6.6 billion).
- Confirm the current market price of B shares relative to the recent average purchase price of DKK 280.34.
- Review the full list of transactions on novonordisk.com for real-time updates beyond August 21, 2026.
- Check the latest Form 20-F or quarterly reports for operational financial metrics (revenue, EPS, cash flow) not included in this 6-K.